Health Care International - Bayer's Novel Anticoagulant Rivaroxaban Recommended For EU Approval - Venous Blood Clot Prevention After Elective Hip Or Knee Replacement Surgery
The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the anticoagulant rivaroxaban (Xarelto®), taken as one tablet, once-daily, for the prevention of venous blood clots (deep vein thrombosis (DVT) and pulmon
Comments